Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Resistance to ADCs in the treatment of solid tumors

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon May 20, 2024 10:34am

103 Views

Post# 36048641

RE:RE:RE:Resistance to ADCs in the treatment of solid tumors

May 20, 2024 - AstraZeneca unveiled plans today, to build a $1.5 billion ADC manufacturing facility in Singapore.

AZ’s interest and investment in ADCs is likely well placed, given that the $10 billion market for the specialized cancer fighters has been tipped to grow more than 15% each year, Paul Tomasic, managing director and head of European healthcare at investment bank Houlihan Lokey, wrote in a note to clients Monday morning.

AstraZeneca is making its manufacturing play as the ADC market grows increasingly crowded with other large-cap pharma players, Tomasic pointed out. Within the last year, AbbVie and Pfizer each closed multibillion-dollar deals in the ADC space, buying out ImmunoGen and Seagen, respectively.

Singapore has become a popular destination for drugmakers in recent years. Back in January, AbbVie said it broke ground on a $223 million expansion of its manufacturing plant in the country to help bolster global biologics capacity. And in March, Novartis started work on its own $256 million Singapore expansion, which will primarily support manufacturing of antibody drugs. Before that, Merck and Sanofi each charted large projects in the country in 2022.

https://www.fiercepharma.com/pharma/astrazeneca-places-15b-bet-end-end-antibody-drug-conjugate-production-singapore

<< Previous

Bullboard Posts

Next >>

How one company is disrupting PoC testing